Evidence map›Paper›PMID 28471497›Full record

ArticleArthritis & rheumatology (Hoboken, N.J.)2017

Haploinsufficiency of NADPH Oxidase Subunit Neutrophil Cytosolic Factor 2 Is Sufficient to Accelerate Full-Blown Lupus in NZM 2328 Mice.

Chaim O Jacob, Ning Yu, Dae-Goon Yoo, Lizet J Perez-Zapata, Emilia Alina Barbu, Mariana J Kaplan, Monica Purmalek, Jeanette T Pingel, Rachel A Idol, Mary C Dinauer

Open access · greenAbstract read
In one paragraph

Article in Arthritis & rheumatology (Hoboken, N.J.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 56 citations in OpenAlex.

  1. Review
  2. Immunometabolism in systemic lupus erythematosus.Nature reviews. Rheumatology · 2025
    Review
  3. Article
  4. Article
  5. Redox Pathogenesis in Rheumatic Diseases.ACR open rheumatology · 2024
    Review
  6. Article
  7. Article
  8. Myeloid cell MHC I expression drives CD8Frontiers in immunology · 2023
    Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Immunogenetics of Lupus Erythematosus.Advances in experimental medicine and biology · 2022
    Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Chaim O JacobUniversity of Southern California School of Medicine, Los Angeles.
Ning YuUniversity of Southern California School of Medicine, Los Angeles.
Dae-Goon YooWashington University School of Medicine in St. Louis, St. Louis, Missouri.
Lizet J Perez-ZapataWashington University School of Medicine in St. Louis, St. Louis, Missouri.
Emilia Alina BarbuWashington University School of Medicine in St. Louis, St. Louis, Missouri.
Mariana J KaplanNational Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, Maryland.
Monica PurmalekNational Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, Maryland.ORCID 0000-0003-2756-161X
Jeanette T PingelWashington University School of Medicine in St. Louis, St. Louis, Missouri.
Rachel A IdolWashington University School of Medicine in St. Louis, St. Louis, Missouri.
Mary C DinauerWashington University School of Medicine in St. Louis, St. Louis, Missouri.
Washington University in St. Louis · USNational Institute of Arthritis and Musculoskeletal and Skin Diseases · USUniversity of Southern California · US

Funding

Systemic AutoimmunityZIAAR041199 · NIAMS · NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES · PI KAPLAN, MARIANA · 2014 to 2025
$32.5M
Pediatric Cardiovascular and Pulmonary Research Training Program.T32HL125241 · NHLBI · WASHINGTON UNIVERSITY · PI Juliane Bubeck Wardenburg, Kory J. Lavine · 2015 to 2026
$4.1M
Elucidation of novel gene variants predisposing to childhood and adult-onset SLER01AR057172 · NIAMS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI JACOB, CHAIM O. · 2010 to 2014
$2.6M
Intramural NIH HHS ZIA AR041199NIAMS NIH HHS R01 AR057172
6 · The paper itself

Abstract

objectiveWe have previously established that the gene for neutrophil cytosolic factor 2 (NCF-2) predisposes to lupus, and we have identified lupus patients with point mutations that are predicted to cause reduced NADPH oxidase activity. We undertook this study to investigate the relationship between reduced leukocyte NADPH oxidase activity and immune dysregulation associated with systemic lupus erythematosus (SLE).

methodsWe generated NCF-2-null mice, in which NADPH oxidase activity is absent, on the nonautoimmune C57BL/6 (B6) mouse background and on the NZM 2328 mouse background, a polygenic model in which mice spontaneously develop lupus. Clinical disease, serology, and immunopathology were evaluated.

resultsNCF-2-null mice on the B6 background were susceptible to Aspergillus fumigatus pneumonia characteristic of chronic granulomatous disease, but did not develop systemic lupus disease. In contrast, NCF-2-null and even NCF-2-haploinsufficient mice on the NZM 2328 background developed accelerated full-blown lupus with significantly accelerated lupus kidney disease. This was characterized by more rapid development of hyperactive B cell and T cell immune compartments, increased expression of type I interferon-responsive genes, and generation of neutrophil extracellular traps, which were observed even in the absence of NADPH oxidase activity.

conclusionJust as patients with chronic granulomatous disease who lack NADPH oxidase rarely develop SLE, NCF-2-null mice on a nonautoimmune background were susceptible to a chronic granulomatous disease-like opportunistic infection but did not develop lupus. In contrast, on a lupus-prone background, even haploinsufficiency of NCF-2 accelerated the development of full-blown lupus disease. This establishes an interaction between reduced oxidase activity and other lupus-predisposing genes, paralleling human SLE-associated variants predicted to have only reduced NADPH oxidase activity.

Indexed as

AnimalsAntimicrobial Cationic PeptidesAspergillus fumigatusB-LymphocytesCathelicidinsDisease ProgressionEnzyme-Linked Immunosorbent AssayExtracellular TrapsGene Expression RegulationGenetic Predisposition to DiseaseGranulomatous Disease, ChronicHaploinsufficiencyInterferon Type IKidneyLupus Erythematosus, SystemicLupus NephritisAntimicrobial Cationic PeptidesCathelicidinsInterferon Type INADPH OxidasesNcf2 protein, mouse

Identifiers

PMID28471497
PMCPMC12351534
OpenAlexW2761187227

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.